Skip to main content

BDX

Stock
Health Care
Medical Instruments & Supplies

Performance overview

BDX Price
Price Chart

Forward-looking statistics

Beta
0.41
Risk
19.95%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.

Company info

SectorHealth Care
IndustryMedical Instruments & Supplies
Employees75K
Market cap$69.5B

Fundamentals

Enterprise value$68.0B
Revenue$20.9B
Revenue per employee—
Profit margin7.18%
Debt to equity76.34

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$5.16
Dividend per share$4.16
Revenue per share$72.21
Avg trading volume (30 day)$469M
Avg trading volume (10 day)$514M
Put-call ratio—

Macro factor sensitivity

Growth-0.6
Credit+2.3
Liquidity+0.4
Inflation-2.6
Commodities-0.1
Interest Rates-0.4

Valuation

Dividend yield2.36%
PEG Ratio11.20
Price to sales2.42
P/E Ratio11.20
Enterprise Value to Revenue3.26
Price to book2.00

Upcoming events

Next earnings dayJuly 31, 2025
Next dividend day—
Ex. dividend dayJune 9, 2025

News

New vaccine panel meeting underway

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on vaccines.

CNBC Television (June 26, 2025)
Becton Dickinson Stock (BDX): Why It's Best To Avoid For Now

Shares of Becton Dickinson and Company BDX are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting until early June 2027. Here's a breakdown of why the stock's structure looks weak under the lens of the Adhishthana Principles, our proprietary cyclical framework combining behavioral archetypes, timing structures, and quantitative signals.

Benzinga (June 25, 2025)
BD Stock Might See Short-term Decline After Warning on Tamponade Tubes

BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.

Zacks Investment Research (May 30, 2025)
Starboard pushes an open door at Becton Dickinson as company seeks to separate its biosciences unit

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The company aims to do just that.

CNBC (February 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free